

研究成果の刊行に関する一覧表

書籍

| 著者氏名 | 論文タイトル名 | 書籍全体の編集者名 | 書 籍 名 | 出版社名 | 出版地 | 出版年 | ページ |
|------|---------|-----------|-------|------|-----|-----|-----|
| 該当なし | | | | | | | |

雑誌

| 発表者氏名 | 論文タイトル名 | 発表誌名 | 巻号 | ページ | 出版年 |
|--|---|------------------|--------|---------|------|
| <u>Koike K</u> , Suyama K, Ito H, Itoh H, Sugiura W. | Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naive chronic hepatitis B patients. | Hepatol Res. | 48(1) | 59-68 | 2018 |
| Joshita S, Yoshizawa K, Umemura T, Ohira H, Takahashi A, Harada K, Hiep NC, Tsuneyama K, Kage M, Nakano M, Kang JH, <u>Koike K</u> , Zeniya M, Yasunaka T, Takaki A, Torimura T, Abe M, Yokosuka O, Tanaka A, Takikawa H. | Clinical features of autoimmune hepatitis with acute presentation: a Japanese nationwide survey. | J Gastroenterol. | [Epub] | | 2018 |
| Iwasa M, Karino Y, Kawaguchi T, Nakanishi H, Miyaaki H, Shiraki M, Nakajima T, Sawada Y, Yoshiji H, Okita K, <u>Koike K</u> . | Relationship of muscle cramps to quality of life and sleep disturbance in patients with chronic liver diseases: a nationwide study. | Liver Int. | [Epub] | | 2018 |
| Hiramine Y, Uojima H, Nakanishi H, Hiramatsu A, Iwamoto T, Kimura M, Kawaratani H, Terai S, Yoshiji H, Uto H, Sakaida I, Izumi N, Okita K, <u>Koike K</u> . | Response criteria of tolvaptan for the treatment of hepatic edema. | J Gastroenterol. | 53(2) | 258-268 | 2018 |
| Fujiwara N, Nakagawa H, Enooku K, Kudo Y, Hayata Y, Nakatsuka T, Tanaka Y, Tateishi R, Hikiba Y, Misumi K, Tanaka M, Hayashi A, Shibahara J, Fukayama M, Arita J, Hasegawa K, Hirschfield H, Hoshida Y, Hirata Y, Otsuka M, Tateishi K, <u>Koike K</u> . | CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity. | Gut | [Epub] | | 2018 |
| Hiramine Y, Uojima H, Nakanishi H, Hiramatsu A, | Response criteria of tolvaptan for the treatment of hepatic | J Gastroenterol. | 53(2) | 258-268 | 2018 |

| | | | | | |
|---|--|-------------------------------|-------------|-----------|------|
| Iwamoto T, Kimura M, Kawaratani H, Terai S, Yoshiji H, Uto H, Sakaida I, <u>Izumi N</u> , Okita K, Koike K. | edema. | | | | |
| Hidaka H, Kokubu S, Sato T, Katsushima S, <u>Izumi N</u> , Igura T, Asahara S, Notsu-mata K, Osaki Y, Tsuji K, Kawanaka H, Akahoshi T, Hirota S, Matsutani S | Antithrombin III for portal vein thrombosis in patients with liver disease: A randomized, double-blind, controlled trial. | Hepatol Res. | 48(3) | E107-E116 | 2018 |
| Kudo M, Cheng AL, Park JW, Park JH, Liang PC, Hidaka H, <u>Izumi N</u> , Heo J, Lee YJ, Sheen IS, Chiu CF, Arioka H, Morita S, Arai Y | Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. | Lancet Gastroenterol Hepatol. | 3(1) | 37-46. | 2018 |
| Kawashima T, Ikari N, Watanabe Y, Kubota Y, Yoshio S, <u>Kanto T</u> , Motohashi S, Shimojo N, Tsuji NM. | Double-Stranded RNA Derived from Lactic Acid Bacteria Augments Th1 Immunity via Interferon- β from Human Dendritic Cells. | Front Immunol. | 9 | 27 | 2018 |
| Shimagaki T, Yoshizumi T, Harimoto N, Yoshio S, Naito Y, Yamamoto Y, Ochiya T, Yoshida Y, <u>Kanto T</u> , Maehara Y. | MicroRNA-125b expression and intrahepatic metastasis are predictors for early recurrence after hepatocellular carcinoma resection. | Hepatol Res. | 48(4) | 313-321. | 2018 |
| Doi H, Hayashi E, Arai J, Tojo M, Morikawa K, Eguchi J, Ito T, <u>Kanto T</u> , Kaplan DE, Yoshida H. | Enhanced B-cell differentiation driven by advanced cirrhosis resulting in hyperglobulinemia. | J Gastroenterol | [Epub] | | 2018 |
| <u>Kudo M</u> , Cheng AL, Park JW, Park JH, Liang PC, Hidaka H, Izumi N, Heo J, Lee YJ, Sheen IS, Chiu CF, Arioka H, Morita S, Arai Y | Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. | Lancet Gastroenterol Hepatol | 3(1) | 37-46 | 2018 |
| Takayasu K, Arii S, Sakamoto M, Matsuyama Y, <u>Kudo M</u> , Kaneko S, Nakashima O, Kadoya M, Izumi N, Takayama T, Ku Y, Kumada T, Kubo S, Kokudo T, Hagiwara Y, Kokudo N | Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤ 2 cm analysed with propensity score weighting. | Liver Int. | 38(3) | 484-493 | 2018 |
| <u>Kudo M</u> | Lenvatinib may drastically change the treatment landscape of hepatocellular carcinoma. | Liver Cancer | 7(1) | 1-19 | 2018 |
| <u>Kudo M</u> | Combination cancer immunotherapy in hepatocellular carcinoma. Liver Cancer | Liver Cancer | 7(1) | 20-27 | 2018 |
| <u>Kudo M</u> , Finn RS, Qin S, Han KH, Ikeda | Lenvatinib versus sorafenib in first-line treatment of patients | Lancet | 391 (10126) | 1163-1173 | 2018 |

| | | | | | |
|---|--|-------------------------------|--------|-----------|------|
| K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL | with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. | | | | |
| Zhu AX, Baron AD, Malfertheiner P, <u>Kudo M</u> , Kawazoe S, Pezet D, Weissinger F, Brandi G, Barone CA, Okusaka T, Wada Y, Park JO, Ryoo BY, Cho JY, Chung HC, Li CP, Yen CJ, Lee KD, Chang SC, Yang L, Abada PB, Chau I | Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Analysis of REACH Trial results by Child-Pugh score. | JAMA Oncol. | [Epub] | | 2018 |
| Kaibori M, Yoshii K, Yokota I, Hasegawa K, Nagashima F, Kubo S, Kon M, Izumi N, Kadoya M, <u>Kudo M</u> , Kumada T, Sakamoto M, Nakashima O, Matsuyama Y, Takayama T, Kokudo N | Liver Cancer Study Group of Japan: Impact of advanced age on survival in patients undergoing resection of hepatocellular carcinoma: report of a Japanese nationwide survey. | Ann Surg. | [Epub] | | 2018 |
| Ikeda M, <u>Kudo M</u> , Aikata H, Nagamatsu H, Ishii H, Yokosuka O, Torimura T, Morimoto M, Ikeda K, Kumada H, Sato T, Kawai I, Yamashita T, Horio H, Okusaka T | Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial. | J Gastroenterol. | [Epub] | | 2018 |
| Minami Y, Minami T, Hagiwara S, Ida H, Ueshima K, Nishida N, Murakami T, <u>Kudo M</u> | Ultrasound-ultrasound image overlay fusion improves real-time control of radiofrequency ablation margin in the treatment of hepatocellular carcinoma. | Eur Radiol. | 28(5) | 1986-1993 | 2018 |
| <u>Kudo M</u> , Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y | Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. | Lancet Gastroenterol Hepatol. | 3(6) | 424-432 | 2018 |
| Kaibori M, Yoshii K, Hasegawa K, Ogawa A, Kubo S, Tateishi R, Izumi N, Kadoya M, <u>Kudo M</u> , Kumada T, Sakamoto M, Nakashima O, Matsuyama Y, Takayama T, Kokudo N | Treatment Optimization for Hepatocellular Carcinoma in Elderly Patients in a Japanese Nationwide Cohort. | Ann Surg. | [Epub] | | 2018 |

| | | | | | |
|--|---|----------------------|--------|----------|------|
| Dietrich CF, Averkiou M, Nielsen MB, Barr RG, Burns PN, Calliada F, Cantisani V, Choi B, Chammas MC, Clevert DA, Claudon M, Correas JM, Cui XW, Cosgrove D, D'Onofrio M, Dong Y, Eisenbrey J, Fontanilla T, Gilja OH, Ignee A, Jenssen C, Kono Y, <u>Kudo M</u> , Lassau N, Lyshchik A, Franca Meloni M, Moriyasu F, Nolsøe C, Piscaglia F, Radzina M, Saftoiu A, Sidhu PS, Sporea I, Schreiber-Dietrich D, Sirlin CB, Stanczak M, Weskott HP, Wilson SR, Willmann JK, Kim TK, Jang HJ, Vezeridis A, Westerway S | How to perform Contrast-Enhanced Ultrasound (CEUS) | Ultrasound Int Open. | 4(1) | E2-E15 | 2018 |
| Nishida N, <u>Kudo M</u> | Immune checkpoint blockade for the treatment of human hepatocellular. | Hep Res. | [Epub] | | 2018 |
| Kaibori M, Yoshii K, Hasegawa K, Ogawa A, <u>Kubo S</u> , Tateishi R, Izumi N, Kadoya M, Kudo M, Kumada T, Sakamoto M, Nakashima O, Matsuyama Y, Takayama T, Kokudo N; Liver Cancer Study Group of Japan | Treatment optimization for hepatocellular carcinoma in elderly patients in a Japanese nationwide cohort | Ann Surg. | [Epub] | | 2018 |
| Takayasu K, Arii S, Sakamoto M, Matsuyama Y, Kudo M, Kaneko S, Nakashima O, Kadoya M, Izumi N, Takayama T, Ku Y, Kumada T, <u>Kubo S</u> , Kokudo T, Hagiwara Y, Kokudo N; Liver Cancer Study Group of Japan | Impact of resection and ablation for single hypovascular HCC \leq 2 cm analyzed with propensity score weighting based on a Japanese nationwide survey | Liver Int. | 38 (3) | 484-493 | 2018 |
| Motoyama H, Tamori A, <u>Kubo S</u> , Uchida-Kobayashi S, Takemura S, Tanaka S, Ohfuji S, Teranishi Y, Kozuka R, Kawamura E, Hagihara A, Morikawa H, Enomoto M, Murakami Y, Kawada N | Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication | PIOS One | 13 (3) | e0194163 | 2018 |
| Wada H, Eguchi H, Nagano H, <u>Kubo S</u> , Nakai T, Kaibori M, Hayashi M, Takemura S, Tanaka S, Nakata | Perioperative allogenic blood transfusion is a poor prognostic factor after hepatocellular carcinoma surgery: a multi-center | Surg Today | 48 (1) | 73-79 | 2018 |

| | | | | | |
|--|---|-----------------------------|--------|---------|------|
| Y, Matsui K, Ishizaki M, Hirokawa F, Komeda K, Uchiyama K, Kon M, Doki Y, Mori M | analysis | | | | |
| Nakano K, Hirahara N, Motomura N, <u>Miyata H</u> , Takamoto S | A report based on the Japan Cardiovascular Surgery Database. 4. Valvular heart surgery. | Gen Thorac Cardiovasc Surg. | 66(1) | 13-18 | 2018 |
| Saito A, Hirahara N, Motomura N, <u>Miyata H</u> , Takamoto S | Current status of cardiovascular surgery in Japan, 2013 and 2014: A report based on the Japan Cardiovascular Surgery Database 3. Coronary artery bypass surgery. | Gen Thorac Cardiovasc Surg. | 66(1) | 8-12 | 2018 |
| Hirata Y, Hirahara N, Murakami A, Motomura N, <u>Miyata H</u> , Takamoto S | Current status of cardiovascular surgery in Japan 2013 and 2014: A report based on the Japan Cardiovascular Surgery Database. 2: Congenital heart surgery. | Gen Thorac Cardiovasc Surg. | 66(1) | 4-7 | 2018 |
| Takamoto S, Motomura N, <u>Miyata H</u> , Tsukihara H | Current status of cardiovascular surgery in Japan, 2013 and 2014: A report based on the Japan Cardiovascular Surgery Database (JCVSD). 1: Mission and history of JCVSD. | Gen Thorac Cardiovasc Surg. | 66(1) | 1-3 | 2018 |
| Hirata Y, <u>Miyata H</u> , Hirahara N, Murakami A, Kado H, Sakamoto K, Sano S, Takamoto S | Long-Term Results of Bilateral Pulmonary Artery Banding Versus Primary Norwood Procedure. | Pediatr Cardiol. | 39(1) | 111-119 | 2018 |
| Kodashima S, Tanaka K, Matsuda K, Fujishiro M, Saito Y, Ohtsuka K, Oda I, Katada C, Kato M, Kida M, Kobayashi K, Hoteya S, Horimatsu T, Matsuda T, Muto M, Yamamoto H, Ryozaawa S, Iwakiri R, Kutsumi H, <u>Miyata H</u> , Kato M, Haruma K, Fujimoto K, Uemura N, Kaminishi M, Tajiri H | First progress report on the Japan Endoscopy Database project. | Dig Endosc. | 30(1) | 20-28 | 2018 |
| Hiki N, Honda M, Etoh T, Yoshida K, Kodera Y, Kakeji Y, Kumamaru H, <u>Miyata H</u> , Yamashita Y, Inomata M, Konno H, Seto Y, Kitano S | Higher incidence of pancreatic fistula in laparoscopic gastrectomy. Real-world evidence from a nationwide prospective cohort study. | Gastric Cancer. | 21(1) | 162-170 | 2018 |
| Kaibori M, Yoshii K, Hasegawa K, Ogawa A, Kubo S, <u>Tateishi R</u> , Izumi N, Kadoya M, Kudo M, Kumada T, Sakamoto M, Nakashima O, Matsuyama Y, Takayama T, Kokudo N, Liver Cancer Study Group of J. | Treatment Optimization for Hepatocellular Carcinoma in Elderly Patients in a Japanese Nationwide Cohort. | Ann Surg | [Epub] | | 2018 |
| Fujiwara N, Nakagawa H, Enooku K, Kudo Y, Hayata Y, Nakatsuka T, Tanaka Y, | CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via | Gut | [Epub] | | 2018 |

| | | | | | |
|---|---|-----------------------------|---------|-------------|------|
| Tateishi R, Hikiba Y, Misumi K, Tanaka M, Hayashi A, Shibahara J, Fukayama M, Arita J, Hasegawa K, Hirschfield H, Hoshida Y, Hirata Y, Otsuka M, Tateishi K, Koike K. | acylcarnitine accumulation in obesity. | | | | |
| Takata A, Otsuka M, Kishikawa T, Yamagami M, Ishibashi R, Sekiba K, Suzuki T, Ohno M, Yamashita Y, Abe T, Masuzaki R, Ikenoue T, <u>Koike K.</u> | RASAL1 is a potent regulator of hepatic stellate cell activity and liver fibrosis. | Oncotarget. | 8(39) | 64840-64852 | 2017 |
| Sekiba K, Yamagami M, Otsuka M, Suzuki T, Kishikawa T, Ishibashi R, Ohno M, Sato M, <u>Koike K.</u> | Transcriptional activation of the MICA gene with an engineered CRISPR-Cas9 system. | Biochem Biophys Res Commun. | 486(2) | 521-525 | 2017 |
| Sato M, Tateishi R, Yasunaga H, Matsui H, Horiguchi H, Fushimi K, <u>Koike K.</u> | Mortality and hemorrhagic complications associated with radiofrequency ablation for treatment of hepatocellular carcinoma in patients on hemodialysis for end-stage renal disease: A nationwide survey. | J Gastroenterol Hepatol. | 32(11) | 1873-1878 | 2017 |
| Nakagawa R, Muroyama R, Saeki C, Goto K, Kaise Y, <u>Koike K.</u> , Nakano M, Matsubara Y, Takano K, Ito S, Saruta M, Kato N, Zeniya M. | miR-425 regulates inflammatory cytokine production in CD4(+) T cells via N-Ras upregulation in primary biliary cholangitis. | J Hepatol. | 66(6) | 1223-1230 | 2017 |
| Nakagawa H, Suzuki N, Hirata Y, Hikiba Y, Hayakawa Y, Kinoshita H, Ihara S, Uchino K, Nishikawa Y, Ijichi H, Otsuka M, Arita J, Sakamoto Y, Hasegawa K, Kokudo N, Tateishi K, <u>Koike K.</u> | Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands. | Proc Natl Acad Sci. U S A | 114(19) | e3806-e3815 | 2017 |
| Kumada H, <u>Koike K.</u> , Suyama K, Ito H, Itoh H, Sugiura W. | Efficacy and safety of tenofovir disoproxil fumarate rescue therapy for chronic hepatitis B patients who failed other nucleos(t)ide analogs. | Hepatol Res. | 47(10) | 1032-1041 | 2017 |
| Hirao C, Mikoshiba N, Shibuta T, Yamahana R, Kawakami A, Tateishi R, Yamaguchi H, <u>Koike K.</u> , Yamamoto-Mitani N. | Adherence to oral chemotherapy medications among gastrointestinal cancer patients visiting an outpatient clinic. | Jpn J Clin Oncol. | 47(9) | 786-794 | 2017 |
| Gonoi W, Hayashi TY, Okuma H, Akahane M, Nakai Y, Mizuno S, Tateishi R, Isayama H, <u>Koike K.</u> , Ohtomo K. | Development of pancreatic cancer is predictable well in advance using contrast-enhanced CT: a case-cohort study. | Eur Radiol. | 27(12) | 4941-4950 | 2017 |
| Murakawa M, Asahina Y, Kawai-Kitahata F, Nakagawa M, Nitta S, Otani S, Nagata H, Kaneko S, Asano Y, Tsunoda T, Miyoshi M, Itsui Y, | Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene ex- | J Med Virol. | 89(7) | 1241-1247 | 2017 |

| | | | | | |
|--|---|------------------|--------|-----------|------|
| Azuma S, Kakinuma S, Tanaka Y, Iijima S, Tsuchiya K, <u>Izumi N</u> , Tohda S, Watanabe M. | pression in chronic hepatitis C patients. | | | | |
| Matsuura K, Sawai H, Ikeo K, Ogawa S, Iio E, Isogawa M, Shimada N, Komori A, Toyoda H, Kumada T, Namisaki T, Yoshiji H, Sakamoto N, Nakagawa M, Asahina Y, Kurosaki M, <u>Izumi N</u> , Enomoto N, Kusakabe A, Kajiwara E, Itoh Y, Ide T, Tamori A, Matsubara M, Kawada N, Shirabe K, Tomita E, Honda M, Kaneko S, Nishina S, Suetsugu A, Hiasa Y, Watanabe H, Genda T, Sakaida I, Nishiguchi S, Takaguchi K, Tanaka E, Sugihara J, Shimada M, Kondo Y, Kawai Y, Kojima K, Nagasaki M, Tokunaga K, Tanaka Y; | Japanese Genome-Wide Association Study Group for Viral Hepatitis. Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection. Gastroenterology. | Gastroenterology | 152(6) | 1383-1394 | 2017 |
| Tamaki N, Kurosaki M, Kusakabe A, Orito E, Joko K, Kojima Y, Kimura H, Uchida Y, Hasebe C, Asahina Y, <u>Izumi N</u> ; | Japanese Red Cross Hospital Liver Study Group. Hepatitis B surface antigen reduction by switching from long-term nucleoside/nucleotide analogue administration to pegylated interferon. | J Viral Hepat. | 24(8) | 672-678 | 2017 |
| Toyoda H, Tada T, Johnson PJ, <u>Izumi N</u> , Kadoya M, Kaneko S, Kokudo N, Ku Y, Kubo S, Kumada T, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kudo M; | Liver Cancer Study Group of Japan. Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey. | J Gastroenterol. | 52(10) | 1112-1121 | 2017 |
| Tamaki N, Kuno A, Matsuda A, Tsujikawa H, Yamazaki K, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Korenaga M, Mizokami M, Kurosaki M, Sakamoto M, Narimatsu H, <u>Izumi N</u> . | Serum Wisteria Floribunda Agglutinin-Positive Sialylated Mucin 1 as a Marker of Progenitor/Biliary Features in Hepatocellular Carcinoma. | Sci Rep. | 7(1) | 244 | 2017 |
| Komiyama Y, Kurosaki M, Nakanishi H, Takahashi Y, Itakura J, Yasui Y, Tamaki N, Takada H, Higuchi M, Gotou T, Kubota Y, Takaura K, Hayashi T, Oh W, Okada M, Enomoto N, <u>Izumi N</u> . | Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio. | PLoS One. | 12(3) | e0174649 | 2017 |
| Yada N, Tamaki N, Koizumi Y, Hirooka M, Nakashima O, Hiasa Y, <u>Izumi N</u> , Kudo M. | Diagnosis of Fibrosis and Activity by a Combined Use of Strain and Shear Wave Imaging in Patients with Liver Disease. | Dig Dis. | 35(6) | 515-520 | 2017 |

| | | | | | |
|---|---|-------------------------|--------|-----------|------|
| Hiraoka A, Michitaka K, Kumada T, <u>Izumi N</u> , Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Kudo M. | Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. | Liver Cancer. | 6(4) | 325-336 | 2017 |
| Nishie A, Goshima S, Haradome H, Hatano E, Imai Y, <u>Kudo M</u> , Matsuda M, Motosugi U, Saitoh S, Yoshimitsu K, Crawford B, Kruger E, Ball G, Honda H | Cost-effectiveness of EOB-MRI for hepatocellular carcinoma in Japan. | Clin Ther. | 39(4) | 738-750 | 2017 |
| Hyodo T, Yada N, Hori M, Maenishi O, Lamb P, Sasaki K, Onoda M, <u>Kudo M</u> , Mochizuki T, Murakami T | Multimaterial decomposition algorithm for the quantification of liver fat content using fast-kilovolt-peak switching dual-energy CT: clinical evaluation. | Radiology | 283(1) | 108-118 | 2017 |
| Ikeda K, <u>Kudo M</u> , Kawazoe S, Osaki Y, Ikeda M, Okusaka T, Tamai T, Suzuki T, Hisai T, Hayato S, Okita K, Kumada H | Phase 2 Study of Lenvatinib in patients with advanced hepatocellular carcinoma. | J Gastroenterol. | 52(4) | 512-519 | 2017 |
| <u>Kudo M</u> , Hatano E, Ohkawa S, Fujii H, Masumoto A, Furuse J, Wada Y, Ishii H, Obi S, Kaneko S, Kawazoe S, Yokosuka O, Ikeda M, Ukai K, Morita S, Tsuji A, Kudo T, Shimada M, Osaki Y, Tateishi R, Sugiyama G, Abada PB, Yang L, Okusaka T, Zhu AX | Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial. | J Gastroenterol. | 52(4) | 494-503 | 2017 |
| Howell J, Pinato DJ, Ramaswami R, Bettinger D, Arizumi T, Ferrari C, Yen C, Gibbin A, Burlone ME, Guaschino G, Sellers L, Black J, Pirisi M, <u>Kudo M</u> , Thimme R, Park JW, Sharma R | On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study. | Aliment Pharmacol Ther. | 45(8) | 1146-1155 | 2017 |
| Ikeda M, Shimizu S, Sato T, Morimoto M, Kojima Y, Inaba Y, Hagihara A, Kudo M ⁷ , Nakamori S, Kaneko S ⁹ , Sugimoto R, Tahara T, Ohmura T, Yasui K, Sato K, Ishii H, Furuse J, Okusaka T | Reply to the Letter to the editor 'Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus Sorafenib for advanced hepatocellular carcinoma: randomized phase II trial' by Fornaro et al. | Ann Oncol. | 28(4) | 903-904 | 2017 |
| Minami Y, Takita M, Tsurusaki M, Yagyu Y, Ueshima K, Murakami T, <u>Kudo M</u> | Semiquantitative prediction of early response of conventional transcatheter arterial chemoembolization for hepatocellular | Hepatol Res. | 47(3) | E113-E119 | 2017 |

| | | | | | |
|---|---|---------------|------------|-------------|------|
| | carcinoma using postprocedural plain cone-beam computed tomography. | | | | |
| Lencioni R, Montal R, Torres F, Park JW, Decaens T, Raoul JL, <u>Kudo M</u> , Chang C, Ríos J, Boige V, Assenat E, Kang YK, Lim HY, Walters I, Llovet JM | Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. | J Hepatol. | 66(6) | 1166-1172 | 2017 |
| Howell J, Pinato DJ, Ramaswami R, Arizumi T, Ferrari C, Gibbin A, Burlone ME, Guaschino G, Toniutto P, Black J, Sellers L, <u>Kudo M</u> , Pirisi M, Sharma R | Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib. | Oncotarget. | 8(22) | 36161-36170 | 2017 |
| El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, <u>Kudo M</u> , Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I | Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. | Lancet | 389(10088) | 2492-2502 | 2017 |
| Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, Yada N, Hagiwara S, Minami Y, Ida H, Komeda Y, Takenaka M, Sakurai T, Watanabe T, Nishida N, <u>Kudo M</u> | The overall survival of patients with hepatocellular carcinoma correlates with the newly defined time to progression after transarterial chemoembolization. | Liver Cancer | 6(3) | 227-235 | 2017 |
| Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, <u>Kudo M</u> , Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX | Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: patient-focused outcome results from the randomised phase III REACH study. | Eur J Cancer. | 81 | 17-25 | 2017 |
| Omata M, Cheng AL, Kokudo N, <u>Kudo M</u> , Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK | Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. | Hepatol Int. | 11(4) | 317-370 | 2017 |
| Kokudo T, Hasegawa K, Matsuyama Y, Takayama | Liver resection for hepatocellular carcinoma associated with | Hepatology | 66(2) | 510-517 | 2017 |

| | | | | | |
|--|---|-------------|-------|---------|------|
| T, Izumi N, Kadoya M, <u>Kudo M</u> , Kubo S, Sakamoto M, Nakashima O, Kumada T, Kokudo N | hepatic vein invasion: a Japanese nationwide survey. | | | | |
| Hagiwara S, Nishida N, Park AM, Komeda Y, Sakurai T, Watanabe T, <u>Kudo M</u> | Contribution of C1485T mutation in the HBx gene to human and murine hepatocarcinogenesis. | Sci Rep. | 7(1) | 10440 | 2017 |
| <u>Kudo M</u> | New Era in the Treatment of Chronic Liver Diseases and Liver Cancer: State-of-the Art Progress in 2017 | Digest Dis. | 35 | 493-497 | 2017 |
| Ida H, Hagiwara S, Kono M, Minami T, Chishina H, Arizumi T, Takita M, Yada N, Minami Y, Ueshima K, Nishida N, <u>Kudo M</u> | Hepatocellular carcinoma after achievement of sustained viral response with daclatasvir and asunaprevir in patients with chronic hepatitis C virus infection. | Digest Dis. | 35(6) | 565-573 | 2017 |
| Iwamoto T, Imai Y, Igura T, Kogita S, Sawai Y, Fukuda K, Yamaguchi Y, Matsumoto Y, Nakahara M, Morimoto O, Ohashi H, Fujita N, <u>Kudo M</u> , Takehara T | Non-hypervascular hypointense hepatic nodules during the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI as a risk factor of intrahepatic distant recurrence after radiofrequency ablation of hepatocellular carcinoma. | Digest Dis. | 35(6) | 574-582 | 2017 |
| Arizumi T, Minami T, Chishina H, Kono M, Takita M, Yada N, Hagiwara S, Minami Y, Ida H, Ueshima K, Kamata K, Minaga K, Komeda Y, Takenaka M, Sakurai T, Watanabe T, Nishida N, <u>Kudo M</u> | Impact of Tumor Factors on survival in Patients with Hepatocellular Carcinoma classified based on Kinki Criteria Stage B2 | Digest Dis. | 35(6) | 583-588 | 2017 |
| Arizumi T, Minami T, Chishina H, Kono M, Takita M, Yada N, Hagiwara S, Minami Y, Ida H, Ueshima K, Kamata K, Minaga K, Komeda Y, Takenaka M, Sakurai T, Watanabe T, Nishida N, <u>Kudo M</u> . | Time to transcatheter arterial chemoembolization refractoriness in patients with hepatocellular carcinoma in Kinki criteria stages B1 and B2. | Digest Dis. | 35(6) | 589-597 | 2017 |
| Ishikawa T, Imai M, Owaki T, Sato H, Nozawa Y, Sano T, Iwanaga A, Seki K, Honma T, Yoshida T, <u>Kudo M</u> | Hemodynamic Changes on Cone-Beam Computed Tomography during Balloon-Occluded Transcatheter Arterial Chemoembolization Using Miriplatin for Hepatocellular Carcinoma: A Preliminary Study. | Digest Dis. | 35(6) | 598-601 | 2017 |
| Hiraoka A, Kumada T, <u>Kudo M</u> , Hirooka M, Koizumi Y, Hiasa Y, Tajiri K, Toyoda H, Tada T, Ochi H, Joko K, Shimada N, Deguchi | Hepatic function during repeated TACE procedures and prognosis after introducing sorafenib in patients with unresectable hepatocellular carcinoma: mul- | Digest Dis. | 35(6) | 602-610 | 2017 |

| | | | | | |
|---|---|------------------|---------|-----------|------|
| A, Ishikawa T, Imai M, Tsuji K, Michitaka K | ticenter analysis. | | | | |
| Ueshima K, Nishida N, <u>Kudo M</u> | Sorafenib-regorafenib sequential therapy in advanced hepatocellular carcinoma: a single-institute experience. | Digest Dis. | 35(6) | 611-617 | 2017 |
| Nishida N, <u>Kudo M</u> | Role of immune checkpoint blockade in the treatment for human hepatocellular carcinoma. | Digest Dis. | 35(6) | 618-622 | 2017 |
| <u>Kudo M</u> | Lenvatinib in advanced hepatocellular carcinoma. | Liver Cancer | 6(4) | 253-263 | 2017 |
| Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, <u>Kudo M</u> | Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in japan: the need for a more detailed evaluation of hepatic function. | Liver Cancer | 6(4) | 325-336 | 2017 |
| Hiraoka A, Michitaka K, Kumada T, <u>Kudo M</u> | ALBI score as a novel tool in staging and treatment planning for hepatocellular carcinoma: advantage of ALBI grade for universal assessment of hepatic function. | Liver Cancer | 6(4) | 377-379 | 2017 |
| Sakurai T, Yada N, Hagiwara S, Arizumi T, Minaga K, Kamata K, Takenaka M, Minami Y, Watanabe T, Nishida N, <u>Kudo M</u> | Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma. | Cancer Sci. | 108(10) | 1996-2003 | 2017 |
| Toyoda H, Tada T, Johnson PJ, Izumi N, Kadoya M, Kaneko S, Kokudo N, Ku Y, Kubo S, Kumada T, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, <u>Kudo M</u> ; Liver Cancer Study Group of Japan | Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey. | J Gastroenterol. | 52(10) | 1112-1121 | 2017 |
| Ogawa C, Morita M, Omura A, Noda T, Kubo A, Matsunaka T, Tamaki H, Shibatoge M, Tsutsui A, Senoh T, Nagano T, Takaguchi K, Tani J, Morishita A, Yoneyama H, Masaki T, Moriya A, Ando M, Deguchi A, Kokudo Y, Minami Y, Ueshima K, Sakurai T, Nishida N, <u>Kudo M</u> | Hand-foot syndrome and post-progression treatment are the good predictors of better survival in advanced hepatocellular carcinoma treated with sorafenib: a multicenter study. | Oncology | 93(S1) | 113-119 | 2017 |
| Izumoto H, Hiraoka A, Ishimaru Y, Murakami T, Kitahata S, Ueki H, Aibiki T, Okudaira T, Miyamoto Y, Yamago H, Iwasaki R, Tomida H, Mori | Validation of newly proposed time to TACE progression (TTTP) in intermediate stage hepatocellular carcinoma cases. | Oncology | 93(S1) | 120-126 | 2017 |

| | | | | | |
|--|--|-------------------------------|---------|---------|------|
| K, Kishida M, Tsubouchi E, Miyata H, Ninomiya T, Kawasaki H, Hirooka M, Matsuura B, Abe M, Hiasa Y, Michitaka K, <u>Kudo M</u> | | | | | |
| <u>Kudo M</u> , Arizumi T | Transarterial Chemoembolization in Combination with Molecular Targeted Agent: Lessons from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2). | Oncology | 93(S1) | 127-134 | 2017 |
| <u>Kudo M</u> | Systemic Therapy for Hepatocellular Carcinoma: 2017 Update. | Oncology | 93(S1) | 135-146 | 2017 |
| <u>Kudo M</u> | Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update. | Oncology | 93(S1) | 147-159 | 2017 |
| Nishida N, <u>Kudo M</u> | Oncogenic signal and tumor microenvironment in hepatocellular carcinoma. | Oncology | 93(S1) | 160-164 | 2017 |
| Yen C, Sharma R, Rimassa L, Arizumi T, Bettinger D, Choo HY, Pressiani T, Burlone ME, Pirisi M, Giordano L, Abdulrahman A, <u>Kudo M</u> , Thimme R, Park JW, Pinato DJ | Treatment stage migration maximizes survival outcomes in patients with hepatocellular carcinoma treated with sorafenib: an observational study. | Liver Cancer | 6(4) | 313-324 | 2017 |
| Cheung TT, Han HS, She WH, Chen KH, Chow PKH, Yoong BK, Lee KF, <u>Kubo S</u> , Tang CN, Wakabayashi G | The Asia Pacific consensus statement on laparoscopic liver resection for hepatocellular carcinoma: A report from 7th Asia-Pacific Primary Liver Cancer Expert Meeting held | Liver Cancer | 7 (1) | 28-39 | 2017 |
| Kaibori M, Kon M, Kitawaki T, Kawaura T, Hasegawa K, Kokudo N, Ariizumi S, Beppu T, Ishizu H, <u>Kubo S</u> , Kamiyama T, Takamura H, Kobayashi T, Kim DS, Wang HJ, Kim JM, Han DH, Park SJ, Kang KJ, Hwang S, Roh Y, You YK, Joh JW, Yamamoto M | Comparison of anatomic and non-anatomic hepatic resection for hepatocellular carcinoma | J Hepatobiliary Pancreat Sci. | 24 (11) | 616-626 | 2017 |
| Shinkawa H, Takemura S, Tanaka S, <u>Kubo S</u> | Portal vein embolization: history and current indication | Visc Med. | 33 (6) | 414-417 | 2017 |
| Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, <u>Kubo S</u> , Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Kudo M | Validation and potential of albumin-bilirubin grade and prognostication in nationwide survey of 46,681 HCC patients in Japan – need for more detailed evaluation of hepatic function | Liver Cancer | 6 (4) | 325-336 | 2017 |

| | | | | | |
|---|---|-------------------------------|------------|-----------|------|
| Nomura S, Sakamoto H, Glenn S, Tsugawa Y, Abe SK, Rahman MM, Brown JC, Ezoe S, Fitzmaurice C, Inokuchi T, Kassebaum NJ, Kawakami N, Kita Y, Kondo N, Lim SS, Maruyama S, <u>Miyata H</u> , Mooney MD, Naghavi M, Onoda T, Ota E, Otake Y, Roth GA, Saito E, Tabuchi T, Takasaki Y, Tanimura T, Uechi M, Vos T, Wang H, Inoue M, Murray CJL, Shibuya K | Population health and regional variations of disease burden in Japan, 1990-2015: a systematic subnational analysis for the Global Burden of Disease Study 2015. | Lancet | 390(10101) | 1521-1538 | 2017 |
| Sawano M, Kohsaka S, Abe T, Inohara T, Maekawa Y, Ueda I, Sueyoshi K, Suzuki M, Noma S, Numasawa Y, <u>Miyata H</u> , Fukuda K, Smolderen KG, Spertus JA | Patterns of statin non-prescription in patients with established coronary artery disease: A report from a contemporary multicenter Japanese PCI registry. | PLoS One | 12(8) | e0182687 | 2017 |
| Takeuchi H, <u>Miyata H</u> , Ozawa S, Udagawa H, Osugi H, Matsubara H, Konno H, Seto Y, Kitagawa Y | Comparison of Short-Term Outcomes Between Open and Minimally Invasive Esophagectomy for Esophageal Cancer Using a Nationwide Database in Japan. | Ann Surg Oncol. | 24(7) | 1821-1827 | 2017 |
| Watanabe T, <u>Miyata H</u> , Konno H, Kawai K, Ishihara S, Sunami E, Hirahara N, Wakabayashi G, Gotoh M, Mori M | Prediction model for complications after low anterior resection based on data from 33,411 Japanese patients included in the National Clinical Database. | Surgery | 161(6) | 1597-1608 | 2017 |
| Ikemura N, Sawano M, Shiraiishi Y, Ueda I, <u>Miyata H</u> , Numasawa Y, Noma S, Suzuki M, Momiyama Y, Inohara T, Hayashida K, Yuasa S, Maekawa Y, Fukuda K, Kohsaka S | Barriers Associated With Door-to-Balloon Delay in Contemporary Japanese Practice. | Circ J. | 81(6) | 815-822 | 2017 |
| Takai H, <u>Miyata H</u> , Motomura N, Sasaki K, Kunihara T, Takamoto S | Comparison of early outcomes of surgical ablation procedures for atrial fibrillation concomitant to non-mitral cardiac surgery: a Japan Adult Cardiovascular Surgery Database study. | Gen Thorac Cardiovasc Surg. | 65(9) | 500-505 | 2017 |
| Inohara T, Kohsaka S, Yamaji K, Amano T, Fujii K, Oda H, Uemura S, Kadota K, <u>Miyata H</u> , Nakamura M; J-PCI Registry Investigators ¹ | J-PCI Registry Investigators. Impact of Institutional and Operator Volume on Short-Term Outcomes of Percutaneous Coronary Intervention: A Report From the Japanese Nationwide Registry. | JACC Cardiovasc Interv. | 10(9) | 918-927 | 2017 |
| Aoki S, <u>Miyata H</u> , Konno H, Gotoh M, Motoi F, Kumamaru H, Wakabayashi G, Kakeji Y, Mori M, Seto Y, Unno M | Risk factors of serious postoperative complications after pancreaticoduodenectomy and risk calculators for predicting postoperative complications: a na- | J Hepatobiliary Pancreat Sci. | 24(5) | 243-251 | 2017 |

| | | | | | |
|--|---|-----------------------------|--------|-----------|------|
| | tionwide study of 17,564 patients in Japan. | | | | |
| Numasawa Y, Sawano M, <u>Miyata H</u> , Ueda I, Noma S, Suzuki M, Kuno T, Kodaira M, Maekawa Y, Fukuda K, Kohsaka S | Outcomes After Percutaneous Coronary Intervention of Acute Coronary Syndrome Complicated With Cardiopulmonary Arrest (from a Japanese Multi-center Registry). | Am J Cardiol. | 119(8) | 1173-1178 | 2017 |
| Miyahara S, <u>Miyata H</u> , Motomura N, Takamoto S, Okita Y ; Japan Cardiovascular Surgery Database Organization | Japan Cardiovascular Surgery Database Organization. Clinical significance of chronic obstructive pulmonary disease in patients undergoing elective total arch replacement: analysis based on the Japan Adult Cardiovascular Surgery Database. | Eur J Cardiothorac Surg. | 51(4) | 761-766 | 2017 |
| Inohara T, Kohsaka S, <u>Miyata H</u> , Sawano M, Ueda I, Maekawa Y, Fukuda K, Jones PG, Cohen DJ, Zhao Z, Spertus JA, Smolderen KG | Prognostic Impact of Subsequent Acute Coronary Syndrome and Unplanned Revascularization on Long-Term Mortality After an Index Percutaneous Coronary Intervention: A Report From a Japanese Multi-center Registry. | J Am Heart Assoc. | 6(11) | e006529 | 2017 |
| Kikuchi H, <u>Miyata H</u> , Konno H, Kamiya K, Tomotaki A, Gotoh M, Wakabayashi G, Mori M | Development and external validation of preoperative risk models for operative morbidities after total gastrectomy using a Japanese web-based nationwide registry. | Gastric Cancer | 20(6) | 987-997 | 2017 |
| Endo S, Ikeda N, Kondo T, Nakajima J, Kondo H, Yokoi K, Chida M, Sato M, Toyooka S, Yoshida K, Okada Y, Sato Y, Okada M, Okumura M, Chihara K, Fukuchi E, <u>Miyata H</u> | Model of lung cancer surgery risk derived from a Japanese nationwide web-based database of 78 594 patients during 2014-2015. | Eur J Cardiothorac Surg. | 52(6) | 1182-1189 | 2017 |
| Shimizu H, Hirahara N, Motomura N, <u>Miyata H</u> , Takamoto S | Current status of cardiovascular surgery in Japan, 2013 and 2014: A report based on the Japan Cardiovascular Surgery Database. 4. Valvular heart surgery. | Gen Thorac Cardiovasc Surg. | 65(12) | 671-678 | 2017 |
| Kawamoto S, <u>Miyata H</u> , Motomura N, Tanemoto K, Takamoto S, Saiki Y | Surgical Outcomes of Isolated Coronary Artery Bypass Grafting for Acute Coronary Syndrome - Based on the Japan Adult Cardiovascular Surgery Database. | Circ J. | 82(1) | 123-130 | 2017 |
| Tamura Y, Kumamaru H, Satoh T, <u>Miyata H</u> , Ogawa A, Tanabe N, Hatano M, Yao A, Abe K, Tsujino I, Fukuda K, Kimura H, Kuwana M, Matsubara H, Tatsumi K ; Japan PH Registry (JAPHR) Network. | Effectiveness and Outcome of Pulmonary Arterial Hypertension-Specific Therapy in Japanese Patients With Pulmonary Arterial Hypertension. | Circ J. | 82(1) | 275-282 | 2017 |
| Sato M, <u>Tateishi R</u> , Yasunaga | Mortality and hemorrhagic com- | J Gastroenterol | 32(11) | 1873- | 2017 |

| | | | | | |
|--|--|-------------------|--------|-----------|------|
| H, Matsui H, Horiguchi H, Fushimi K, Koike K. | plications associated with radiofrequency ablation for treatment of hepatocellular carcinoma in patients on hemodialysis for end-stage renal disease: A nationwide survey. | Hepatol. | | 1878 | |
| Kudo M, Hatano E, Ohkawa S, Fujii H, Masumoto A, Furuse J, Wada Y, Ishii H, Obi S, Kaneko S, Kawazoe S, Yokosuka O, Ikeda M, Ukai K, Morita S, Tsuji A, Kudo T, Shimada M, Osaki Y, <u>Tateishi R</u> , Sugiyama G, Abada PB, Yang L, Okusaka T, Zhu AX. | Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial. | J Gastroenterol. | 52(4) | 494-503 | 2017 |
| Hirao C, Mikoshiba N, Shibuta T, Yamahana R, Kawakami A, <u>Tateishi R</u> , Yamaguchi H, Koike K, Yamamoto-Mitani N. | Adherence to oral chemotherapy medications among gastrointestinal cancer patients visiting an outpatient clinic. | Jpn J Clin Oncol. | 47(9) | 786-794 | 2017 |
| Gonoi W, Hayashi TY, Okuma H, Akahane M, Nakai Y, Mizuno S, <u>Tateishi R</u> , Isayama H, Koike K, Ohtomo K. | Development of pancreatic cancer is predictable well in advance using contrast-enhanced CT: a case-cohort study. | Eur Radiol. | 27(12) | 4941-4950 | 2017 |